J.E. Hamer-Maansson - Incyte | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 20 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

MPN-052 Ruxolitinib Treatment in Patients with Polycythemia Vera (PV) Reduces JAK2 Allele Burden and Improves Hematocrit Control and Symptom Burden

Claire N. Harrison, Jean-Jacques Kiladjian, Francesca Palandri,J.E. Hamer-Maansson,Evan Braunstein,Francesco Passamonti

Clinical Lymphoma Myeloma and Leukemia (2024)

引用0浏览0引用

MPN-051 the Impact of New or Worsening Anemia on Clinical Outcomes in 2233 Patients with Myelofibrosis Treated with Ruxolitinib: Results from the Expanded-Access JUMP Study

Vikas Gupta, Paola Guglielmelli,J.E. Hamer-Maansson,Evan Braunstein, Haifa Kathrin

Clinical Lymphoma Myeloma and Leukemia (2024)

引用0浏览0引用

Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

Abdulraheem Yacoub,Roger M. Lyons,Evan M. Braunstein,J. E. Hamer-Maansson,Tricia Kalafut, Ruben A. Mesa

Clinical Lymphoma Myeloma & Leukemia（2024）

引用0浏览0引用

Clinical and Disease Characteristics of Patients with Myelofibrosis and Essential Thrombocythemia Who Harbor a Calreticulin (CALR) Gene Mutation: Subanalysis of the MOST Study

Stephen T. Oh,Naveen Pemmaraju, Niyati Nathwani,Evan M. Braunstein,J. E. Hamer-Maansson,Tricia Kalafut,Ellen K. Ritchie

Clinical Lymphoma Myeloma & Leukemia (2024): S199-S199

引用0浏览0引用

Ruxolitinib Treatment in Patients with Polycythemia Vera (PV) Reduces JAK2 Allele Burden and Improves Hematocrit Control and Symptom Burden

Claire N. Harrison, Jean-Jacques Kiladjian, Francesca Palandri,J.E. Hamer-Maansson,Evan Braunstein,Francesco Passamonti

Clinical Lymphoma Myeloma and Leukemia (2024)

引用0浏览0引用

Treatment Comparison of Hydroxyurea Versus Ruxolitinib in Essential Thrombocythaemia: A Matched-Cohort Analysis

Michael R. Grunwald,Ellen K. Ritchie, Elisa Rumi,Albert Assad,J. E. Hamer-Maansson,Jingbo Yu,Tricia Kalafut,Evan Braunstein,Francesco Passamonti

EJHAEMno. 4 (2024): 778-783

引用0浏览0WOS引用

The Impact of New or Worsening Anemia on Clinical Outcomes in 2233 Patients with Myelofibrosis Treated with Ruxolitinib: Results from the Expanded-Access JUMP Study

Vikas Gupta, Paola Guglielmelli,J.E. Hamer-Maansson,Evan Braunstein, Haifa Kathrin Al-Ali

Clinical Lymphoma Myeloma and Leukemia (2024)

引用0浏览0引用

Association Between Elevated White Blood Cell Counts and Thrombotic Events in Polycythemia Vera: Analysis from REVEAL

Aaron T. Gerds,Ruben Mesa,John M. Burke,Michael R. Grunwald,Brady L. Stein,Peg Squier,Jingbo Yu,J. E. Hamer-Maansson,Stephen T. Oh

Bloodno. 16 (2024): 1646-1655

引用0浏览0WOS引用

MPN-100 High Rate of Disease Progression in Patients with Low-Risk Myelofibrosis (MF) Enrolled in the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Michael R. Grunwald,Aaron T. Gerds,Apurv Agrawal,Evan M. Braunstein,J.E. Hamer-Maansson,Tricia Kalafut,John Mascarenhas

Clinical Lymphoma Myeloma & Leukemia (2024): S413-S413

引用0浏览0引用

Ruxolitinib Treatment in Polycythemia Vera Results in Reduction in JAK2 Allele Burden in Addition to Improvement in Hematocrit Control and Symptom Burden

Claire N. Harrison,Jean-Jacques Kiladjian,Francesca Palandri,J. E. Hamer-Maansson,Evan M. Braunstein,Francesco Passamonti

Bloodno. Supplement 1 (2023): 4553-4553

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn